menu
    • menu
    [{"orgOrder":0,"company":"Tracer","sponsor":"Var2 Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"89-Zr DFO-N-Suc-F8scFv","moa":"Fibronectin EDB","graph1":"Oncology","graph2":"Phase I","graph3":"Tracer","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tracer \/ Tracer","highestDevelopmentStatusID":"6","companyTruncated":"Tracer \/ Tracer"},{"orgOrder":0,"company":"Tracer","sponsor":"Akston Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"AKS-452","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tracer","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tracer \/ Akston Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Tracer \/ Akston Biosciences"},{"orgOrder":0,"company":"Tracer","sponsor":"Aplagon","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FINLAND","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"89-Zr DFO-APAC","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Tracer","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tracer \/ Tracer","highestDevelopmentStatusID":"6","companyTruncated":"Tracer \/ Tracer"}]

    Find Clinical Drug Pipeline Developments & Deals by Tracer

    Menu

    Tracer

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Tracer

                            Netherlands arrow
                            OTS 2025
                            Not Confirmed

                            Tracer

                            Netherlands arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 89-Zr DFO-N-Suc-F8scFv

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Var2 Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PET-imaging of Two Vartumabs in Patients With Solid Tumors

                            Details : 89-Zr DFO-N-Suc-F8scFv is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            October 17, 2024

                            Lead Product(s) : 89-Zr DFO-N-Suc-F8scFv

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Var2 Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Tracer

                            Netherlands arrow
                            OTS 2025
                            Not Confirmed

                            Tracer

                            Netherlands arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 89-Zr DFO-APAC

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Recipient : Aplagon

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety, Tolerability, and Biodistribution of [89Zr]Zr-DFO-APAC in Subjects With PAOD/CLI and Healthy Volunteer...

                            Details : 89-Zr DFO-APAC is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Arterial Occlusive Diseases.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            January 12, 2024

                            Lead Product(s) : 89-Zr DFO-APAC

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Recipient : Aplagon

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Tracer

                            Netherlands arrow
                            OTS 2025
                            Not Confirmed

                            Tracer

                            Netherlands arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AKS-452

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Akston Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Tracer to Support Akston Biosciences’ Phase 1 Clinical Study of AKS-452, an Innovative Anti-Covid-19 Vaccine

                            Details : TRACER will will provide regulatory services, oversight of local manufacturing contractors as well as Phase 1 Study preparation and clinical site management for Akston Biosciences' Phase 1 clinical testing in of its lead COVID-19 vaccine candidate, AKS-4...

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            September 01, 2020

                            Lead Product(s) : AKS-452

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Akston Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth